The company's patented MANF technology could be worth billions. The "Brain Mapping Program" will substantially increase its value.
gov'f funding cut weeks ago... no need to read any news or research it further. Widely known that the sequester cut funding.
Noted bio-tech analyst Jason Napadano says its current valuation should be .20 without him attributing any value to the company's Amarantus Diagnostics subsidiary. Read his recent SeekingAlpha articles about the company.
Get in today under a dime.
Read the recent Yahoo news.
Still under a dime.